Biocryst Pharmaceuticals Inc
BioCryst Reports Third Quarter 2026 Financial Results
Total net revenue of $180.3 million and ORLADEYO® net revenue of $174.8 million —
Company newsroom
Biocryst Pharmaceuticals Inc
NASDAQ:BCRX
1 releases
Company newsroom
NASDAQ:BCRX
1 releases
Total net revenue of $180.3 million and ORLADEYO® net revenue of $174.8 million —